European Journal of Dermatology


Treatment with injectable platelet-rich fibrin in a rat model of melasma Volume 33, numéro 5, September-October 2023

  • [1] Lee BW, Schwartz RA, Janniger CK. Melasma. G Ital Dermatol Venereol. 2017;152:36-45.
  • [2] Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. Int J Mol Sci. 2016;17:824.
  • [3] Çayırlı M, Çalışkan E, Açıkgöz G, Erbil AH, Ertürk G. Regression of melasma with platelet-rich plasma treatment. Ann Dermatol. 2014;26:401-2.
  • [4.] Garg S, Khillan K, Bharija SC. Platelet-rich plasma therapy in the treatment of recalcitrant melasma. Dermatol Surg. 2019;45:482-4. .. .
  • [5] Sarkar R, Gupta M. Platelet-rich plasma in melasma-a systematic review. Dermatol Surg. 2022;48:131-4.
  • [6] Tekam PS, Belgaumkar VA. Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: a split-face comparative study. Dermatol Ther. 2022;35. e15761
  • [7] Zhao L, Hu M, Xiao Q. Efficacy and safety of platelet-rich plasma in melasma: a systematic review and meta-analysis. Dermatol Ther (Heidelb). 2021;11:1587-97.
  • [8] Zhou S, Sun C, Huang S. Efficacy of adjunctive bioactive materials in the treatment of periodontal intrabony defects: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:8670832.
  • [9] Dohan Ehrenfest DM, Bielecki T, Jimbo R. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012;13:1145-52.
  • [10] Varela HA, Souza JCM, Nascimento RM. Injectable platelet rich fibrin: cell content, morphological, and protein characterization. Clin Oral Investig. 2019;23:1309-18.
  • [11] Shashank B, Bhushan M. Injectable Platelet-Rich Fibrin (PRF): the newest biomaterial and its use in various dermatological conditions in our practice: a case series. J Cosmet Dermatol. 2021;20:1421-6.
  • [12] Yang J, Zeng J, Lu J. Mechanisms of ultraviolet-induced melasma formation: a review. J Dermatol. 2022;49:1201-10.
  • [13] Abdel-Rahman AT, Abdel-Hakeem FG, Ragaie MH. Clinical, dermoscopic, and histopathologic evaluation of vitamin C versus PRP, with microneedling in the treatment of mixed melasma: a split-face, comparative study. Dermatol Ther. 2022;35. e15239
  • [14] Acar A, Ozturk A, Sokmen N, Unal I, Ertam Sagduyu I. Evaluation of platelet-rich plasma efficacy in melasma. J Cosmet Laser Ther. 2022;24:36-9.
  • [15] Deng T, Cheng F, Guo S, Cheng H, Wu J. Application of PRP in chloasma: a meta-analysis and systematic review. Comput Intell Neurosci. 2022;2022:7487452.
  • [16] Gamea MM, Kamal DA, Donia AA, Hegab DS. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J Dermatolog Treat. 2022;33:798-804.
  • [17] Patil NK, Bubna AK. A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma. Dermatol Ther. 2022;35. e15534
  • [18] Lee HM, Shen EC, Shen JT, Fu E, Chiu HC, Hsia YJ. Tensile strength, growth factor content and proliferation activities for two platelet concentrates of platelet-rich fibrin and concentrated growth factor. J Dent Sci. 2020;15:141-6.
  • [19] Karimi K, Rockwell H. The benefits of platelet-rich fibrin. Facial Plast Surg Clin North Am. 2019;27:331-40.
  • [20] Wang Z, Mudalal M, Sun Y. The effects of Leukocyte-Platelet Rich Fibrin (L-PRF) on suppression of the expressions of the pro-inflammatory cytokines, and proliferation of Schwann cell, and neurotrophic factors. Sci Rep. 2020;10:2421.
  • [21] Kim DS, Park SH, Park KC. Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int J Biochem Cell Biol. 2004;36:1482-91.
  • [22] Hofny ERM, Hussein MRA, Ghazally A, Ahmed AM, Abdel-Motaleb AA. Increased expression of TGF-beta protein in the lesional skins of melasma patients following treatment with platelet-rich plasma. J Cosmet Laser Ther. 2019;21:382-9.
  • [23] Yun WJ, Bang SH, Min KH, Kim SW, Lee MW, Chang SE. Epidermal growth factor and epidermal growth factor signaling attenuate laser-induced melanogenesis. Dermatol Surg. 2013;39:1903-11.
  • [24] Babbush KM, Babbush RA, Khachemoune A. The therapeutic use of antioxidants for melasma. J Drugs Dermatol. 2020;19:788-92.
  • [25] Li R, Liu Y, Xu T. The additional effect of autologous platelet concentrates to coronally advanced flap in the treatment of gingival recessions: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:2587245.
  • [26] Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients’ own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018;44:87-95.
  • [27] Ozbey R, Okur MI. The use of 4% hydroquinone, 0.1% tretinoin, and 0.1% betamethasone creams to prevent hyperpigmentation of split-thickness skin grafts in Long-Evans rats. J Cosmetic Dermatol. 2020;19:2663-8.
  • [28] Xiaoyao Liu, Ting Wang, Peixuan Zhu. Current status of the animal model of melasma. Chin J Exp Formulol. 2020;26:200-8.
  • [29] Mingsan Miao, Jenna Fu, Lihua Caa. Specification for the preparation of melasma animal models. New Med Clin Pharmacol Tradit Chin Med. 2017;28:649-53.